Compare MEC & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | OCGN |
|---|---|---|
| Founded | 1945 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 387.3M |
| IPO Year | 2019 | N/A |
| Metric | MEC | OCGN |
|---|---|---|
| Price | $18.18 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.50 | $7.00 |
| AVG Volume (30 Days) | 160.7K | ★ 6.2M |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $533,523,000.00 | $5,370,000.00 |
| Revenue This Year | N/A | $35.88 |
| Revenue Next Year | $9.93 | N/A |
| P/E Ratio | $30.81 | ★ N/A |
| Revenue Growth | N/A | ★ 14.26 |
| 52 Week Low | $11.72 | $0.52 |
| 52 Week High | $19.82 | $1.96 |
| Indicator | MEC | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 51.18 |
| Support Level | $18.02 | $1.47 |
| Resistance Level | $18.71 | $1.70 |
| Average True Range (ATR) | 0.76 | 0.14 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 42.74 | 21.43 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").